Cohort demographics at registration
| Treatment arm | |||
| Nivolumab | Nivolumab+ipilimumab | Total | |
| (N=39) | (N=40) | (N=79) | |
| Age group (years), n (%) | |||
| <65 | 20 (51.3%) | 26 (65.0%) | 46 (58.2%) |
| 65+ | 19 (48.7%) | 14 (35.0%) | 33 (41.8%) |
| Sex, n (%) | |||
| Female | 15 (38.5%) | 18 (45.0%) | 33 (41.8%) |
| Male | 24 (61.5%) | 22 (55.0%) | 46 (58.2%) |
| Race, n (%) | |||
| White | 34 (87.2%) | 36 (90.0%) | 70 (88.6%) |
| Black or African American | 4 (10.3%) | 1 (2.5%) | 5 (6.3%) |
| Asian | 1 (2.6%) | 0 (0.0%) | 1 (1.3%) |
| Native Hawaiian or Pacific Islander | 0 (0.0%) | 2 (5.0%) | 2 (2.5%) |
| Patient unsure | 0 (0.0%) | 1 (2.5%) | 1 (1.3%) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 33 (84.6%) | 34 (85.0%) | 67 (84.8%) |
| Hispanic or Latino | 3 (7.7%) | 2 (5.0%) | 5 (6.3%) |
| Not reported: patient refused or data not available | 1 (2.6%) | 2 (5.0%) | 3 (3.8%) |
| Unknown: patient is unsure of their ethnicity | 2 (5.1%) | 2 (5.0%) | 4 (5.1%) |
| Histological subtype, n (%) | |||
| GIST | 10 (25.6%) | 11 (27.5%) | 21 (26.6%) |
| DDLPS | 15 (38.5%) | 14 (35.0%) | 29 (36.7%) |
| UPS | 14 (35.9%) | 15 (37.5%) | 29 (36.7%) |
| ECOG performance status, n (%) | |||
| 0 | 15 (38.5%) | 23 (57.5%) | 38 (48.1%) |
| 1 | 24 (61.5%) | 17 (42.5%) | 41 (51.9%) |
| Histological grade (differentiation), n (%) | |||
| G1 (well differentiated) | 4 (10.3%) | 2 (5.0%) | 6 (7.6%) |
| G2 (moderately differentiated) | 3 (7.7%) | 7 (17.5%) | 10 (12.7%) |
| G3 (poorly differentiated) | 20 (51.3%) | 21 (52.5%) | 41 (51.9%) |
| GX (grade cannot be assessed) | 12 (30.8%) | 10 (25.0%) | 22 (27.8%) |
| Number of prior therapies, n (%) | |||
| 1 | 11 (28.2%) | 10 (25.0%) | 21 (26.6%) |
| 2 | 8 (20.5%) | 12 (30.0%) | 20 (25.3%) |
| 3+ | 20 (51.3%) | 18 (45.0%) | 38 (48.1%) |
DDLPS, dedifferentiated liposarcoma; ECOG, Eastern Cooperative Oncology Group; GIST, gastrointestinal stromal tumor; UPS, undifferentiated pleomorphic sarcoma.